343 5. Complicanze precoci Bibliografia [1] Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consen- sus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Trans- plant 2005;11(12):945–56. [2] Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015 Mar;21(3):389401.e1. doi: 10.1016/j.bbmt.2014.12.001. Epub 2014 Dec 18. PMID: 25529383; PMCID: PMC4329079. [3] Zeiser R, Blazar BR. Acute graft-versus-host disease - biologic process, prevention, and therapy. N Engl J Med 2017; 377: 2167–2179. [4] Kamal Rodin NS, Ismail NA, Abdul Wahid SF, Jamil A, Syed Zakaria SZ, Syed Abd Kadir SS, Lee BR, Bakrin IH, Wan Jamaludin WF. Epidemiology and clinical profiles of cutaneous graft versus host disease in allogeneic peripheral blood stem cell transplantation. Malays J Pathol. 2021 Dec;43(3):361-373. PMID: 34958057. [5] Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828. [6] MacDonald KP, Shlomchik WD, Reddy P. Biology of graft- versus-host responses: recent insights. Biol Blood Marrow Transplant. 2013;19(1 Suppl):S10–4. [7] Häusermann P, Walter RB, Halter J, Biedermann BC, Tichelli A, Itin P, Gratwohl A. Cutaneous graft-versus-host disease: a guide for the dermatologist. Dermatology. 2008;216(4):287-304. doi: 10.1159/000113941. Epub 2008 Jan 29. PMID: 18230976. [8] Lerner KG, Kao GF, Storb R, Buckner CD, Clift RA, Thomas ED. Histopathology of graft-vs-host reaction (GvHR) in human recipients of marrow from HLA-matched sibling donors. Transplant Proc. 1974;6(4):367–371 [9] Surjana D, Robertson I, Kennedy G, James D, Weedon D. Acute cutaneous graft-versus-host disease resembling type II (atypical adult) pityriasis rubra pilaris. Australas J Dermatol. 2015;56(1):e21–e23. doi: 10.1111/ajd.12108. [10] Matsushita T, Hasegawa M, Shirasaki F, Fujimoto M, Yamazaki H, Sato S, et al. A case of acute cutaneous graft-versus-host disease mimicking psoriasis vulgaris. Dermatology. 2008;216(1):64– 67. doi: 10.1159/000109361. [11] Huang J, Pol-Rodriguez M, Silvers D, Garzon MC. Acquired ichthyosis as a manifestation of acute cutaneous graftversus-host disease. Pediatr Dermatol. 2007;24(1):49–52. doi: 10.1111/j.1525-1470.2007.00333.x. [12] Dignan FL, Clark A, Amrolia P, Cornish J, Jackson G, Mahendra P, Scarisbrick JJ, Taylor PC, Hadzic N, Shaw BE, Potter MN; Haemato-oncology Task Force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation. Diagnosis and management of acute graft-versus-host disease. Br J Haematol. 2012 Jul;158(1):30-45. doi: 10.1111/j.13652141.2012.09129.x. Epub 2012 Apr 26. PMID: 22533831. [13] Ting W, Stone MS, Racila D, et al. Toxic epidermal necrolysislike acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions. Lupus 2004; 13: 941–950. [14] Kavand S, Lehman JS, Hashmi S, et al. Cutaneous manifestations of graft-versus-host disease: role of the dermatologist. Int J Dermatol 2017; 56: 131–140. [15] Byun HJ, Yang JI, Kim BK, Cho KH. Clinical differentiation of acute cutaneous graft-versus-host disease from drug hypersensitivity reactions. J Am Acad Dermatol. 2011;65(4):726–732. doi: 10.1016/j.jaad.2010.07.042. [16] Strong Rodrigues K, Oliveira-Ribeiro C, de Abreu Fiuza Gomes S, Knobler R. Cutaneous Graft-Versus-Host Disease: Diagnosis and Treatment. Am J Clin Dermatol. 2018 Feb;19(1):3350. doi: 10.1007/s40257-017-0306-9. PMID: 28656563; PMCID: PMC5797560. [17] Gomes N, Huynh A, Borel C, Guenounou S, Recher C, Barres B, Vigarios E, Sibaud V. Oral acute graft versus host disease after donor lymphocyte infusions: Clinicopathological characterization in a monocenter cohort. Oral Oncol. 2021 Mar;114:105082. doi: 10.1016/j.oraloncology.2020.105082. [18] Saliba RM, de Lima M, Giralt S, Andersson B, Khouri IF, Hosing C, et al. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood. 2007;109(7):2751–2758. [19] Pe as PF, Zaman S. Many faces of graft-versus-host disease. Australas J Dermatol. 2010;51(1):1–10. doi: 10.1111/j.14400960.2009.00577.x. [20] Hu SW, Cotliar J. Acute graft-versus-host disease following hematopoietic stem-cell transplantation. Dermatol Ther. 2011;24(4):411–423. doi: 10.1111/j.1529-8019.2011.01436.x. [21] Kaminska-Winciorek G, Czerw T, Kruzel T, Giebel S. Dermoscopic follow-up of the skin toward acute graft-versus-host-disease in patients after allogeneic hematopoietic stem cell transplantation. Biomed Res Int. 2016; Article ID 4535717. doi:10.1155/2016/4535717. [22] Ruiz-Genao DP, GF-Villalta MJ, Pe as PF, Fraga J, García-Díez A, Fernández-Herrera J. Pustular acral erythema in a patient with acute graft-versus-host disease. J Eur Acad Dermatol Venereol. 2003;17(5):550–553. doi: 10.1046/j.1468-3083.2003.00801.x. [23] Ion D, Stevenson K, Woo SB, Ho VT, Soiffer R, Antin JH, et al. Characterization of oral involvement in acute graft-versushost disease. Biol Blood Marrow Transplant. 2014;20(11):1717–1721. doi: 10.1016/j.bbmt.2014.06.031. [24] Vassalo C, Brazzelli V, Zecca M, Locatelli F, Alessandrino PE, Borroni G. Isomorphic cutaneous graft-versus-host disease reaction after ultraviolet exposure: clinical, histological and direct immunofluorescence studies of four allo-transplanted patients. J Eur Acad Dermatol Venereol. 2009;23(8):913–918. doi: 10.1111/j.1468-3083.2009.03220.x. [25] Hillen U, Häusermann P, Massi D, Janin A, Wolff D, Lawitschka A, et al. Consensus on performing skin biopsies, laboratory workup, evaluation of tissue samples and reporting of the results in patients with suspected cutaneous graft-versus-host disease. J Eur Acad Dermatol Venereol. 2015;29(5):948–954. doi: 10.1111/ jdv.12737 [26] Jang S, Kim IS, Youn SW. Chronic graft-versus-host disease mimicking psoriasis in a patient with hemophagocytic lymphohistiocytosis. Ann Dermatol. 2016;28(1):90–93. doi: 10.5021/ ad.2016.28.1.90.3 [27] Kunitomi A, Lida H, Kamiya Y, Hayashi M, Sao H. Successful treatment using tacrolimus ointment for cutaneous graft-versushost disease. Int J Hematol. 2008;88(4):465–467. doi: 10.1007/ s12185-008-0197-x. [28] Olson KA, West K, McCarthy PL. Toxic tacrolimus levels after application of topical tacrolimus and use of occlusive dressing in two bone marrow transplant recipients with cutaneous graftversus-host disease. Pharmacotherapy. 2014;34(6):e60–e64. doi: 10.1002/phar.1418. [29] Rashidi A, DiPersio JF, Sandmaier BM, Colditz GA, Weisdorf DJ. Steroids versus steroids plus additional agent in frontline treatment of acute graft-versus-host disease: a systematic re-
RkJQdWJsaXNoZXIy ODUzNzk5